An Empirical Assessment of the Business Value Derived from Implementing Mobile Technology: A Case Study of Two Organizations

Mobile technologies are argued to offer unprecedented opportunities for organizations and individuals. In order for organizations to be persuaded that investment in mobile technologies is not only worthwhile, but also important to the achievement of corporate goals and objectives, then it is important to evaluate the potential of mobile technology so that the derivation of business value and the related risks involved in implementing mobile devices and services in an organization can be understood. This paper aims at understanding the organizational value that could be derived from investments in mobile technology. We present two in-depth case studies of mobile technology implementation in health care organizations. These studies show that deriving business value from the adoption and implementation of mobile devices does not seem at all certain, but is contingent upon clear business objectives and a willingness to make business changes to embrace the transformation to core business processes which are driven by the mobile technologies

Panel of multi-pathway analysis of 112 crude drugs/herbs.

<p>Heatmap of activity levels of 112 crude drugs/herbs across 10 reporters. Activity levels were indicated by Z-scores calculated from the relative transcriptional activities of individual crude drugs/herbs across different reporters, and by colors presented at the top of the figure. The crude drugs/herbs belonging to three traditional conceptions (heat-clearing and dampness-drying herbs, the acrid and warm exterior-resolving herbs, and the acrid and cool exterior-resolving herbs) are shown in green, red, and blue, respectively. Five major groupings are shown as the lines on the tree of crude drugs/herbs, and the enriched major groupings of three traditional conceptions are shown in green, red, and blue, respectively. **<i>P</i> <0.01 and *<i>P <0</i>.<i>05</i> by chi-square test.</p

Schematic outline of the multi-pathway analysis using 112 extracts of crude drugs/herbs.

<p>A549 cells were co-transfected with the reporter plasmids containing the transcription factor-binding site upstream of the luciferase gene with the <i>Renilla</i> luciferase gene. After the addition of the extract of crude drugs/herbs at 100 μg/ml, the cell lysates were subjected to dual-luciferase assay. The luciferase activity of each crude drug/herb was normalized to that of the vehicle control. The result of CREB reporter was shown as an example. Data are mean of two independent experiments. The hierarchical clustering and heatmap were performed using the R statistical package.</p

The different effects on each pathway by experiment-based classification.

<p>(A) Relative luciferase activity by each crude drug/herb was normalized to that of the vehicle control. The averages of relative luciferase activity of two major groupings containing exterior-resolving herbs (n = 50, filled bars) and others (n = 62, open bars) are shown. Data are the means ± S.D. of each grouping. *<i>p</i> <0.01 by two-way ANOVA followed by the Bonferroni <i>post-hoc</i> test compared with exterior-resolving medicines and others. (B) The averages of relative luciferase activity of each major groupings containing the acrid and warm exterior-resolving herbs (n = 24, filled bars) and the acrid and cool exterior-resolving herbs (n = 26, shadow bars) are shown. *<i>p</i> <0.01 by two-way ANOVA followed by the Bonferroni <i>post-hoc</i> test compared with warm and cool exterior-resolving medicines. Other conditions are similar to Fig 3A. (C) A549 cells were treated with vehicle (open bars), Perilla Herb (filled bars) or Bupleurum Root (shadow bars) for 48 h. NR4A1 (left panel) or HSP90B1 (right panel) was quantified by real-time RT-PCR. Relative mRNA expression was normalized to the value of each mRNA in vehicle-treated cells. Data are shown as the mean ± SD of three independent experiments.</p